Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2011, Article ID 136064, 11 pages
http://dx.doi.org/10.1155/2011/136064
Review Article

Clostridium difficile Infection and Inflammatory Bowel Disease: A Review

Division of Gastroenterology, Feinberg School of Medicine, Northwestern University, 676 N St Clair Street, Suite 1400, Chicago, IL 60611, USA

Received 27 February 2011; Revised 17 June 2011; Accepted 5 July 2011

Academic Editor: Genevieve B. Melton-Meaux

Copyright © 2011 Preetika Sinh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. C. McDonald, M. Owings, and D. B. Jernigan, “Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003,” Emerging Infectious Diseases, vol. 12, no. 3, pp. 409–415, 2006. View at Google Scholar · View at Scopus
  2. J. Pépin, L. Valiquette, M. E. Alary et al., “Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity,” Canadian Medical Association Journal, vol. 171, no. 5, pp. 466–472, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. P. Hookman and J. S. Barkin, “Clostridium difficile associated infection, diarrhea and colitis,” World Journal of Gastroenterology, vol. 15, no. 13, pp. 1554–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. Centers for Disease Control and Prevention (CDC), “Severe Clostridium difficile-associated disease in populations previously at low risk—four states,” Morbidity and Mortality Weekly Report, vol. 54, no. 47, pp. 1201–1205, 2005. View at Google Scholar
  5. A. N. Ananthakrishnan, E. L. McGinley, and D. G. Binion, “Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease,” Gut, vol. 57, no. 2, pp. 205–210, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Issa, A. Vijayapal, M. B. Graham et al., “Impact of Clostridium difficile on inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 3, pp. 345–351, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. F. Rodemann, E. R. Dubberke, K. A. Reske, D. H. Seo, and C. D. Stone, “Incidence of Clostridium difficile infection in inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 3, pp. 339–344, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. R. Dubberke and A. I. Wertheimer, “Review of current literature on the economic burden of Clostridium difficile infection,” Infection Control and Hospital Epidemiology, vol. 30, no. 1, pp. 57–66, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. L. Kyne, M. B. Hamel, R. Polavaram, and C. P. Kelly, “Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile,” Clinical Infectious Diseases, vol. 34, no. 3, pp. 346–353, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. J. A. O'Brien, B. J. Lahue, J. J. Caro, and D. M. Davidson, “The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences,” Infection Control and Hospital Epidemiology, vol. 28, no. 11, pp. 1219–1227, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. E. R. Dubberke, K. A. Reske, M. A. Olsen, L. C. McDonald, and V. J. Fraser, “Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients,” Clinical Infectious Diseases, vol. 46, no. 4, pp. 497–504, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. G. Bartlett, T. W. Chang, and M. Gurwith, “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia,” The New England Journal of Medicine, vol. 298, no. 10, pp. 531–534, 1978. View at Google Scholar · View at Scopus
  13. J. G. Bartlett, N. Moon, and T. W. Chang, “Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis,” Gastroenterology, vol. 75, no. 5, pp. 778–782, 1978. View at Google Scholar · View at Scopus
  14. G. C. Nguyen, G. G. Kaplan, M. L. Harris, and S. R. Brant, “A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1443–1450, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. Ricciardi, J. W. Ogilvie Jr., P. L. Roberts, P. W. Marcello, T. W. Concannon, and N. N. Baxter, “Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases,” Diseases of the Colon and Rectum, vol. 52, no. 1, pp. 40–45, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. N. Powell, S. E. Jung, and B. Krishnan, “Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent?” Gut, vol. 57, no. 8, pp. 1183–1184, 2008. View at Google Scholar · View at Scopus
  17. J. Starr, “Clostridium difficile associated diarrhoea: diagnosis and treatment,” British Medical Journal, vol. 331, no. 7515, pp. 498–501, 2005. View at Google Scholar · View at Scopus
  18. M. F. G. Rocha, M. E. T. Maia, L. R. P. S. Bezerra et al., “Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin- 1β, tumor necrosis factor alpha, and leukotrienes,” Infection and Immunity, vol. 65, no. 7, pp. 2740–2746, 1997. View at Google Scholar · View at Scopus
  19. T. S. Steiner, C. A. Flores, T. T. Pizarro, and R. L. Guerrant, “Fecal lactoferrin, interleukin-1β, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 6, pp. 719–722, 1997. View at Google Scholar · View at Scopus
  20. M. Warny, J. Pepin, A. Fang et al., “Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe,” The Lancet, vol. 366, no. 9491, pp. 1079–1084, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. Reineke, S. Tenzer, M. Rupnik et al., “Autocatalytic cleavage of Clostridium difficile toxin B,” Nature, vol. 446, no. 7134, pp. 415–419, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. Warny and C. P. Kelly, “Pathogenicity of Clostridium difficile toxins,” in Microbial Pathogenesis and the Intestinal Epithelial Cell, G. Hecht, Ed., pp. 503–524, American Society for Microbiology Press, Washington, D.C, USA, 2003. View at Google Scholar
  23. S. T. Cartman, J. T. Heap, S. A. Kuehne, A. Cockayne, and N. P. Minton, “The emergence of “hypervirulence” in Clostridium difficile,” International Journal of Medical Microbiology, vol. 300, no. 6, pp. 387–395, 2010. View at Google Scholar
  24. L. V. McFarland, “Update on the changing epidemiology of Clostridium difficile-associated disease,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 5, no. 1, pp. 40–48, 2008. View at Google Scholar
  25. L. C. McDonald, G. E. Killgore, A. Thompson et al., “An epidemic, toxin gene-variant strain of Clostridium difficile,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2433–2441, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. Drudy, T. Quinn, R. O'Mahony, L. Kyne, P. Ó'Gaora, and S. Fanning, “High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 6, pp. 1264–1267, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. P. Kelly, “A 76-year-old man with recurrent clostridium difficile associated diarrhea: review of c difficile infection,” Journal of the American Medical Association, vol. 301, no. 9, pp. 954–962, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. H. J. Epple, “Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease,” Digestive Diseases, vol. 27, no. 4, pp. 555–559, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. G. Bartlett and D. N. Gerding, “Clinical recognition and diagnosis of Clostridium difficile infection,” Clinical Infectious Diseases, vol. 46, no. 1, pp. S12–S18, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. J. G. Bartlett, “Antibiotic-associated diarrhea,” The New England Journal of Medicine, vol. 346, no. 5, pp. 334–339, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. D. N. Gerding, S. Johnson, L. R. Peterson, M. E. Mulligan, and J. Silva, “Clostridium difficile-associated diarrhea and colitis,” Infection Control and Hospital Epidemiology, vol. 16, no. 8, pp. 459–477, 1995. View at Google Scholar · View at Scopus
  32. P. J. Bingley and G. M. Harding, “Clostridium difficile colitis following treatment with metronidazole and vancomycin,” Postgraduate Medical Journal, vol. 63, no. 745, pp. 993–994, 1987. View at Google Scholar · View at Scopus
  33. J. Pepin, N. Saheb, M. A. Coulombe et al., “Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec,” Clinical Infectious Diseases, vol. 41, no. 9, pp. 1254–1260, 2005. View at Google Scholar
  34. S. M. Pear, T. H. Williamson, K. M. Bettin, D. N. Gerding, and J. N. Galgiani, “Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use,” Annals of Internal Medicine, vol. 120, no. 4, pp. 272–277, 1994. View at Google Scholar · View at Scopus
  35. L. V. McFarland, “Renewed interest in a difficult disease: Clostridium difficile infections—Epidemiology and current treatment strategies,” Current Opinion in Gastroenterology, vol. 25, no. 1, pp. 24–35, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Schneeweiss, J. Korzenik, D. H. Solomon, C. Canning, J. Lee, and B. Bressler, “Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 3, pp. 253–264, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. R. Kariv, U. Navaneethan, P. G. K. Venkatesh, R. Lopez, and B. Shen, “Impact of Clostridium difficile infection in patients with ulcerative colitis,” Journal of Crohn's and Colitis, vol. 1, pp. 34–40, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Dial, J. A. C. Delaney, A. N. Barkun, and S. Suissa, “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease,” Journal of the American Medical Association, vol. 294, no. 23, pp. 2989–2995, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. Dial, J. A. C. Delaney, V. Schneider, and S. Suissa, “Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy,” Canadian Medical Association Journal, vol. 175, no. 7, pp. 745–748, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. D. Howell, V. Novack, P. Grgurich et al., “Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection,” Archives of Internal Medicine, vol. 170, no. 9, pp. 784–790, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. W. Kim, K. L. Lee, J. B. Jeong et al., “Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea,” World Journal of Gastroenterology, vol. 16, no. 28, pp. 3573–3577, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. D. O. Lowe, M. M. Mamdani, A. Kopp, D. E. Low, and D. N. Juurlink, “Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study,” Clinical Infectious Diseases, vol. 43, no. 10, pp. 1272–1276, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. S. Naggie, B. A. Miller, K. B. Zuzak et al., “A case-control study of community-associated clostridium difficile Infection: no role for proton pump inhibitors,” The American Journal of Medicine, vol. 124, no. 3, pp. 276.e1–276.e7, 2011. View at Google Scholar
  44. D. N. Gerding, C. A. Muto, and R. C. Owens, “Treatment of Clostridium difficile infection,” Clinical Infectious Diseases, vol. 46, supplement 1, pp. S32–S42, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. Ben-Horin, M. Margalit, P. Bossuyt et al., “Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection,” Clinical Gastroenterology and Hepatology, vol. 7, no. 9, pp. 981–987, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. J. T. LaMont and Y. M. Trnka, “Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease,” The Lancet, vol. 1, no. 8165, pp. 381–383, 1980. View at Google Scholar · View at Scopus
  47. C. Greenfield, J. R. A. Ramirez, R. E. Pounder et al., “Clostridium difficile and inflammatory bowel disease,” Gut, vol. 24, no. 8, pp. 713–717, 1983. View at Google Scholar
  48. L. Gurian, K. Klein, and T. T. Ward, “Role of Clostridium difficile and Campylobacter jejuni in relapses of inflammatory bowel disease,” Western Journal of Medicine, vol. 138, no. 3, pp. 359–360, 1983. View at Google Scholar · View at Scopus
  49. P. Rolny, G. Jarnerot, and R. Mollby, “Occurrence of Clostridium difficile toxin in inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 18, no. 1, pp. 61–64, 1983. View at Google Scholar · View at Scopus
  50. R. P. Bolton, R. J. Sherriff, and A. E. Read, “Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease?” The Lancet, vol. 1, no. 8165, pp. 383–384, 1980. View at Google Scholar · View at Scopus
  51. Y. M. Trnka and J. T. LaMont, “Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease,” Gastroenterology, vol. 80, no. 4, pp. 693–396, 1981. View at Google Scholar · View at Scopus
  52. P. Weber, M. Koch, W. R. Heizmann, M. Scheurlen, H. Jenss, and F. Hartmann, “Microbic superinfection in relapse of inflammatory bowel disease,” Journal of Clinical Gastroenterology, vol. 14, no. 4, pp. 302–308, 1992. View at Google Scholar · View at Scopus
  53. M. Mylonaki, L. Langmead, A. Pantes, F. Johnson, and D. S. Rampton, “Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool,” European Journal of Gastroenterology & Hepatology, vol. 16, no. 8, pp. 775–778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. A. M. Meyer, N. N. Ramzan, E. V. Loftus, R. I. Heigh, and J. A. Leighton, “The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease,” Journal of Clinical Gastroenterology, vol. 38, no. 9, pp. 772–775, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Jodorkovsky, Y. Young, and M. T. Abreu, “Clinical outcomes of patients with ulcerative colitis and co-existing clostridium difficile infection,” Digestive Diseases and Sciences, vol. 55, no. 2, pp. 415–420, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. R. Caprilli, M. A. Gassull, J. C. Escher et al., “European evidence based consensus on the diagnosis and management of Crohn's disease: Special situations,” Gut, vol. 55, supplement 1, pp. i36–i58, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. M. Issa, A. N. Ananthakrishnan, and D. G. Binion, “Clostridium difficile and inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 14, no. 10, pp. 1432–1442, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. E. Tsironi, P. M. Irving, R. M. Feakins, and D. S. Rampton, “‘Diversion‘ colitis caused by Clostridium difficile infection: report of a case,” Diseases of the Colon and Rectum, vol. 49, no. 7, pp. 1074–1077, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. B. Shen, J. R. Goldblum, T. L. Hull, F. H. Remzi, A. E. Bennett, and V. W. Fazio, “Clostridium difficile-associated pouchitis,” Digestive Diseases and Sciences, vol. 51, no. 12, pp. 2361–2364, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. S. D. Mann, J. Pitt, R. G. Springall, and A. V. Thillainayagam, “Clostridium difficile infection—an unusual cause of refractory pouchitis: report of a case,” Diseases of the Colon and Rectum, vol. 46, no. 2, pp. 267–270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Shen, F. H. Remzi, and V. W. Fazio, “Fulminant Clostridium difficile-associated pouchitis with a fatal outcome,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 8, pp. 492–495, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. S. Ben-Horin, M. Margalit, P. Bossuyt et al., “Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection,” Journal of Crohn's and Colitis, vol. 4, no. 2, pp. 194–198, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. C. P. Kelly and J. T. LaMont, “Clostridium difficile infection,” Annual Review of Medicine, vol. 49, pp. 375–390, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. R. Fekety and A. B. Shah, “Diagnosis and treatment of Clostridium difficile colitis,” Journal of the American Medical Association, vol. 269, no. 1, pp. 71–75, 1993. View at Publisher · View at Google Scholar · View at Scopus
  65. B. E. Laughon, R. P. Viscidi, S. L. Gdovin, R. H. Yolken, and J. G. Bartlett, “Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens,” Journal of Infectious Diseases, vol. 149, no. 5, pp. 781–788, 1984. View at Google Scholar
  66. S. H. Cohen, D. N. Gerding, S. Johnson et al., “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA),” Infection Control and Hospital Epidemiology, vol. 31, no. 5, pp. 431–455, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. L. R. Peterson, R. U. Manson, S. M. Paule et al., “Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea,” Clinical Infectious Diseases, vol. 45, no. 9, pp. 1152–1160, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. Y. C. Manabe, J. M. Vinetz, R. D. Moore, C. Merz, P. Charache, and J. G. Bartlett, “Clostridium difficile colitis: an efficient clinical approach to diagnosis,” Annals of Internal Medicine, vol. 123, no. 11, pp. 835–840, 1995. View at Google Scholar · View at Scopus
  69. R. Nelson, “Antibiotic treatment for Clostridium difficile-associated diarrhea in adults,” Cochrane Database of Systematic Reviews, no. 3, p. CD004610, 2007. View at Google Scholar · View at Scopus
  70. D. G. Teasley, D. N. Gerding, M. M. Olson et al., “Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis,” The Lancet, vol. 2, no. 8358, pp. 1043–1046, 1983. View at Google Scholar
  71. D. M. Musher, S. Aslam, N. Logan et al., “Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole,” Clinical Infectious Diseases, vol. 40, no. 11, pp. 1586–1590, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. F. A. Zar, S. R. Bakkanagari, K. M. L. S. T. Moorthi, and M. B. Davis, “A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity,” Clinical Infectious Diseases, vol. 45, no. 3, pp. 302–307, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. C. Wenisch, B. Parschalk, M. Hasenhündl, A. M. Hirschl, and W. Graninger, “Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea,” Clinical Infectious Diseases, vol. 22, no. 5, pp. 813–818, 1996. View at Google Scholar · View at Scopus
  74. D. Lagrotteria, S. Holmes, M. Smieja, F. Smaill, and C. Lee, “Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea,” Clinical Infectious Diseases, vol. 43, no. 5, pp. 547–552, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. T. S. Pelaez, R. Blazquez, P. Catalan, P. Munoz, and E. Bouza, “Metronidazole resistance in Clostridium difficile: a new emerging problem?” in Proceedings of the Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract E, pp. 34–50, October 1994.
  76. T. Pelaez, E. Cercenado, L. Alcala et al., “Metronidazole resistance in Clostridium difficile is heterogeneous,” Journal of Clinical Microbiology, vol. 46, no. 9, pp. 3028–3032, 2008. View at Google Scholar
  77. T. Pelaez, L. Alcala, R. Alonso, M. Rodriguez-Creixems, J. M. Garcia-Lechuz, and E. Bouza, “Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin,” Antimicrob Agents Chemother, vol. 46, no. 6, pp. 1647–1650, 2002. View at Google Scholar
  78. E. L. Larson and B. E. Laughon, “Comparison of four antiseptic products containing chlorhexidine gluconate,” Antimicrob Agents Chemother, vol. 31, no. 10, pp. 1572–1574, 1987. View at Google Scholar
  79. D. M. Musher, S. Aslam, N. Logan et al., “Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole,” Clinical Infectious Diseases, vol. 40, no. 11, pp. 1586–1590, 2005. View at Publisher · View at Google Scholar · View at PubMed
  80. T. J. Louie, M. A. Miller, K. M. Mullane et al., “Fidaxomicin versus vancomycin for Clostridium difficile infection,” The New England Journal of Medicine, vol. 364, no. 5, pp. 422–431, 2011. View at Google Scholar
  81. A. J. Brink, D. Bizos, K. D. Boffard et al., “Guideline: appropriate use of tigecycline.(guideline)(clinical report),” South African Medical Journal, vol. 100, no. 6, pp. 388–394, 2010. View at Google Scholar
  82. C. L. Lu, C. Y. Liu, C. H. Liao, Y. T. Huang, H. P. Wang, and P. R. Hsueh, “Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole,” International Journal of Antimicrobial Agents, vol. 35, no. 3, pp. 311–312, 2010. View at Publisher · View at Google Scholar · View at PubMed
  83. B. L. Herpers, B. Vlaminckx, O. Burkhardt et al., “Intravenous tigecycline as adjunctive or alternative therapy for severe refractory clostridium difficile infection,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1732–1735, 2009. View at Publisher · View at Google Scholar · View at PubMed
  84. C. E. Nord, E. Sillerstrom, E. Wahlund et al., “Effect of tigecycline on normal oropharyngeal and intestinal microflora,” Antimicrob Agents Chemother, vol. 50, no. 10, pp. 3375–3380, 2006. View at Google Scholar
  85. R. P. Bolton and M. A. Culshaw, “Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile,” Gut, vol. 27, no. 10, pp. 1169–1172, 1986. View at Google Scholar
  86. A. N. Ananthakrishnan, “Clostridium difficile infection: epidemiology, risk factors and management,” Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 1, pp. 17–26, 2011. View at Google Scholar
  87. P. Kopterides, C. Papageorgiou, A. Antoniadou et al., “Failure of tigecycline to treat severe Clostridium difficile infection,” Anaesthesia and Intensive Care, vol. 38, no. 4, pp. 755–758, 2010. View at Google Scholar
  88. J. M. Tung, L. R. Dolovich, and C. H. Lee, “Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review,” Canadian Journal of Gastroenterology, vol. 23, no. 12, pp. 817–821, 2009. View at Google Scholar
  89. L. V. McFarland, “Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections,” Anaerobe, vol. 15, no. 6, pp. 274–280, 2009. View at Publisher · View at Google Scholar · View at PubMed
  90. L. V. McFarland, “Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease,” American Journal of Gastroenterology, vol. 101, no. 4, pp. 812–822, 2006. View at Google Scholar
  91. A. Pillai and R. Nelson, “Probiotics for treatment of Clostridium difficile-associated colitis in adults,” Cochrane Database of Systematic Reviews, no. 1, p. CD004611, 2008. View at Google Scholar
  92. M. E. Mulligan, S. D. Miller, L. V. McFarland, H. C. Fung, and R. Y. Y. Kwok, “Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile,” Clinical Infectious Diseases, vol. 16, supplement 4, pp. S239–S244, 1993. View at Google Scholar
  93. S. McPherson, C. J. Rees, R. Ellis, S. Soo, and S. J. Panter, “Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea,” Diseases of the Colon and Rectum, vol. 49, no. 5, pp. 640–645, 2006. View at Publisher · View at Google Scholar · View at PubMed
  94. J. Salcedo, S. Keates, C. Pothoulakis et al., “Intravenous immunoglobulin therapy for severe Clostridium difficile colitis,” Gut, vol. 41, no. 3, pp. 366–370, 1997. View at Google Scholar
  95. A. Hassoun and F. Ibrahim, “Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis,” American Journal Geriatric Pharmacotherapy, vol. 5, no. 1, pp. 48–51, 2007. View at Publisher · View at Google Scholar
  96. P. Juang, S. J. Skledar, N. K. Zgheib et al., “Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea,” American Journal of Infection Control, vol. 35, no. 2, pp. 131–137, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. M. S. Abougergi, A. Broor, W. Cui, and B. G. Jaar, “Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature,” Journal of Hospital Medicine, vol. 5, no. 1, pp. E1–E9, 2010. View at Publisher · View at Google Scholar · View at PubMed
  98. M. S. Abougergi and J. H. Kwon, “Intravenous immunoglobulin for the treatment of clostridium difficile infection: a review,” Digestive Diseases and Sciences, pp. 19–26, 2010. View at Publisher · View at Google Scholar · View at PubMed
  99. K. Koss, M. A. Clark, D. S. A. Sanders, D. Morton, M. R. B. Keighley, and J. Goh, “The outcome of surgery in fulminant Clostridium difficile colitis,” Colorectal Disease, vol. 8, no. 2, pp. 149–154, 2006. View at Publisher · View at Google Scholar · View at PubMed
  100. A. D. Olivas, K. Umanskiy, B. Zuckerbraun, and J. C. Alverdy, “Avoiding colectomy during surgical management of fulminant clostridium difficile colitis,” Surgical Infections, vol. 11, no. 3, pp. 299–305, 2010. View at Publisher · View at Google Scholar · View at PubMed
  101. J. C. Byrn, D. C. Maun, D. S. Gingold, D. T. Baril, J. J. Ozao, and C. M. Divino, “Predictors of mortality after colectomy for fulminant Clostridium difficile colitis,” Archives of Surgery, vol. 143, no. 2, pp. 150–154, 2008. View at Publisher · View at Google Scholar · View at PubMed
  102. A. J. Greenstein, J. C. Byrn, L. P. Zhang, K. A. Swedish, A. E. Jahn, and C. M. Divino, “Risk factors for the development of fulminant Clostridium difficile colitis,” Surgery, vol. 143, no. 5, pp. 623–629, 2008. View at Publisher · View at Google Scholar · View at PubMed
  103. P. Butala and C. M. Divino, “Surgical aspects of fulminant Clostridium difficile Colitis,” American Journal of Surgery, vol. 200, no. 1, pp. 131–135, 2010. View at Publisher · View at Google Scholar · View at PubMed
  104. S. Aslam, R. J. Hamill, and D. M. Musher, “Treatment of Clostridium difficile-associated disease: old therapies and new strategies,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 549–557, 2005. View at Publisher · View at Google Scholar · View at PubMed
  105. L. V. McFarland, G. W. Elmer, and C. M. Surawicz, “Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease,” American Journal of Gastroenterology, vol. 97, no. 7, pp. 1769–1775, 2002. View at Publisher · View at Google Scholar
  106. F. J. Tedesco, D. Gordon, and W. C. Fortson, “Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis,” American Journal of Gastroenterology, vol. 80, no. 11, pp. 867–868, 1985. View at Google Scholar
  107. S. S. Yoon and L. J. Brandt, “Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients,” Journal of Clinical Gastroenterology, vol. 44, no. 8, pp. 562–566, 2010. View at Publisher · View at Google Scholar · View at PubMed
  108. F. Rohlke, C. M. Surawicz, and N. Stollman, “Fecal Flora Reconstitution for recurrent clostridium difficile infection: results and methodology,” Journal of Clinical Gastroenterology, vol. 44, no. 8, pp. 567–570, 2010. View at Publisher · View at Google Scholar · View at PubMed
  109. S. Johnson, C. Schriever, M. Galang, C. P. Kelly, and D. N. Gerding, “Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin,” Clinical Infectious Diseases, vol. 44, no. 6, pp. 846–848, 2007. View at Publisher · View at Google Scholar · View at PubMed
  110. L. V. McFarland, C. M. Surawicz, R. N. Greenberg et al., “A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease,” Journal of the American Medical Association, vol. 271, no. 24, pp. 1913–1918, 1994. View at Publisher · View at Google Scholar
  111. I. Lowy, D. C. Molrine, B. A. Leav et al., “Treatment with monoclonal antibodies against Clostridium difficile toxins,” The New England Journal of Medicine, vol. 362, no. 3, pp. 197–205, 2010. View at Publisher · View at Google Scholar · View at PubMed
  112. L. V. McFarland, M. E. Mulligan, R. Y. Y. Kwok, and W. E. Stamm, “Nosocomial acquisition of Clostridium difficile infection,” The New England Journal of Medicine, vol. 320, no. 4, pp. 204–210, 1989. View at Google Scholar
  113. M. H. Samore, L. Venkataraman, P. C. DeGirolami, R. D. Arbeit, and A. W. Karchmer, “Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea,” The American Journal of Medicine, vol. 100, no. 1, pp. 32–40, 1996. View at Google Scholar
  114. R. C. Owens, “Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists,” Pharmacotherapy, vol. 26, no. 3, pp. 299–311, 2006. View at Publisher · View at Google Scholar · View at PubMed
  115. J. L. Mayfield, T. Leet, J. Miller, and L. M. Mundy, “Environmental control to reduce transmission of Clostridium difficile,” Clinical Infectious Diseases, vol. 31, no. 4, pp. 995–1000, 2000. View at Publisher · View at Google Scholar · View at PubMed
  116. W. A. Rutala and D. J. Weber, “Uses of inorganic hypochlorite (bleach) in health-care facilities,” Clinical Microbiology Reviews, vol. 10, no. 4, pp. 597–610, 1997. View at Google Scholar
  117. J. A. Otter, G. L. French, N. M. T. Adams, D. Watling, and M. J. Parks, “Hydrogen peroxide vapour decontamination in an overcrowded tertiary care referral centre: some practical answers,” Journal of Hospital Infection, vol. 62, no. 3, pp. 384–385, 2006. View at Publisher · View at Google Scholar · View at PubMed
  118. J. Ojajarvi, P. Makela, and I. Rantasalo, “Failure of hand disinfection with frequent hand washing: a need for prolonged field studies,” Journal of Hygiene, vol. 79, no. 1, pp. 107–119, 1977. View at Google Scholar
  119. E. L. Larson, P. I. Eke, M. P. Wilder, and B. E. Laughon, “Quantity of soap as a variable in handwashing,” Infection Control, vol. 8, no. 9, pp. 371–375, 1987. View at Google Scholar · View at Scopus
  120. E. Larson, J. J. Leyden, K. J. McGinley, G. L. Grove, and G. H. Talbot, “Physiologic and microbiologic changes in skin related to frequent handwashing,” Infection Control, vol. 7, no. 2, pp. 59–63, 1986. View at Google Scholar
  121. J. M. Boyce and D. Pittet, “Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force,” Infection Control and Hospital Epidemiology, vol. 23, no. 12, pp. S3–S40, 2002. View at Google Scholar
  122. A. Apisarnthanarak, J. E. Zack, J. L. Mayfield et al., “Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile,” Clinical Infectious Diseases, vol. 39, no. 4, pp. 601–602, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. G. W. Kaatz, S. D. Gitlin, D. R. Schaberg et al., “Acquisition of Clostridium difficile from the hospital environment,” American Journal of Epidemiology, vol. 127, no. 6, pp. 1289–1294, 1988. View at Google Scholar · View at Scopus
  124. J. S. Fordtran, “Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial,” Proceedings (Baylor University. Medical Center), vol. 19, no. 1, pp. 3–12, 2006. View at Google Scholar
  125. R. B. Kerr, D. I. McLaughlin, and L. W. Sonnenberg, “Control of Clostridium difficile colitis outbreak by treating asymptomatic carriers with metronidazole,” American Journal of Infection Control, vol. 18, no. 5, pp. 332–335, 1990. View at Google Scholar · View at Scopus
  126. B. S. Bender, R. Bennett, B. E. Laughon et al., “Is Clostridium difficile endemic in chronic-care facilities?” The Lancet, vol. 2, no. 8497, pp. 11–13, 1986. View at Google Scholar
  127. L. V. McFarland, “Alternative treatments for Clostridium difficile disease: what really works?” Journal of Medical Microbiology, vol. 54, no. 2, pp. 101–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Aboudola, K. L. Kotloff, L. Kyne et al., “Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A,” Infection and Immunity, vol. 71, no. 3, pp. 1608–1610, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Sougioultzis, L. Kyne, D. Drudy et al., “Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea,” Gastroenterology, vol. 128, no. 3, pp. 764–770, 2005. View at Publisher · View at Google Scholar · View at Scopus
  130. N. S. Taylor, G. M. Thorne, and J. G. Bartlett, “Comparison of two toxins produced by Clostridium difficile,” Infection and Immunity, vol. 34, no. 3, pp. 1036–1043, 1981. View at Google Scholar · View at Scopus
  131. I. R. Poxton, “Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections,” Future Microbiology, vol. 5, no. 4, pp. 539–548, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus